Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — Society for Investigative Dermatology 2026
19 slides from Corvus Pharmaceuticals's conference presentation, May 2026
Slide 1: Soquelitinib, an ITK inhibitor, Produces Prolonged Drug-Free Remissions in Atopic Dermatitis
Society for Investigative Dermatology 2026, ID # LB1154 Soquelitinib, an ITK inhibitor, Produces Prolonged Drug-Free Remissions in Atopic Dermatitis Albert S. Chiou, MD Clinical Professor, Dermatology and Director of Clinical Research in the Department of Dermatology Stanford University Medical Cent
Slide 2: Disclosures
Disclosures Corvus Pharmaceuticals – Investigator (Grants/Research Funding/Clinical Advisory Board); AbbVie – Investigator (Grants/Research Funding); Abeona Therapeutics – Investigator (Grants/Research Funding); Eli Lilly and Company – Investigator (Grants/Research Funding); Phoenix Tissue Repair –
Slide 3: Background
Background ITK blockade leads to reduction in Th2, Th17 • ITK (interleukin-2-inducible T cell kinase) is “Th1 skewing” expressed in T, NK and ILC-2 cells • Soquelitinib is an oral, selective covalent inhibitor of ITK TH1 Th1 cells play a role in cancer cell T-bet and viral elimination – Nanomolar bi
Slide 4: Background
Background • ITK (interleukin-2-inducible T cell kinase) is ITK blockade leads to switch to Treg expressed in T, NK and ILC-2 cells • Soquelitinib is an oral, selective covalent inhibitor of ITK TH1 T-bet – Nanomolar binding to ITK while sparing RLK – Inhibits Th2 and Th17 differentiation and inhibi
Slide 5: Atopic Dermatitis Placebo Control Phase 1 Design
Atopic Dermatitis Placebo Control Phase 1 Design Soquelitinib 100 mg BID Cohort 1 Randomized N = 12 Study Design 3:1 N =16 4 weeks Placebo • Endpoints: treatment N=4 • Primary: safety Soquelitinib 200 mg QD • Secondary: % change in EASI, EASI75, Randomized N = 12 Cohort 2 3:1 EASI90, IGA 0 or 1 Part
Slide 6: Patient Baseline Characteristics
Patient Baseline Characteristics 4-week 8-week Cohorts 1 and 2 Cohort 3 Cohorts 1–3 Cohort 4 Soquelitinib Soquelitinib Soquelitinib 100 mg BID or 200 mg QD 200 mg BID Placebo 200 mg BID Placebo (n=24) (n=12) (n=12) (n=12) (n=12) Age, mean (range), yrs 44.4 46.4 38.8 40.5 42.3 (21–66) (25–71) (20–62)
Slide 7: Efficacy Results at 4 Weeks
Efficacy Results at 4 Weeks Cohorts 1–3 Soquelitinib Placebo Cohorts 1 and 2 Cohort 3 Combined (N=24) (N=12) (N=12) EASI 75 (%pts) 29 50 0 IGA 0 or 1 (%pts) 21 25 0 EASI 50 (%pts) 75 83 58 EASI 90 (%pts) 4 8 0 Change EASI Mean % Reduction 54.6 64.8 34.4
Slide 8: Mean Percent Reduction in EASI
Mean Percent Reduction in EASI Cohorts 1, 2, and 3
Slide 9: Immune Rebalance
Immune Rebalance Durable remission with increase in Tregs in Cohort 3 Treg increase in blood 200 On Treatment Off Treatment PBO Combined % change over baseline 150 SQL Cohort 1 SQL Cohort 2 100 SQL Cohort 3 50 0 -50 D1 D28 D58 • Change from baseline at Day 28 and at Day 58 (n=9 Cohort 1, n=12 Cohort
Slide 10: Rebound Following Dupilumab and JAKi
Rebound Following Dupilumab and JAKi Worsening within 4 weeks of stopping therapy Dupilumab Abrocitinib LS mean percent improvement (± SE) in EASI score from SOLO baseline during SOLO-CONTINUE (MI) JAMA Dermatol. 2020;156(2):131 JAMA Dermatol. 2019;155(12):1371
Slide 11: Efficacy Results at 8 Weeks
Efficacy Results at 8 Weeks Cohort 4 achieved 75% EASI 75 Cohort 4 (200 mg BID) 8-week Soquelitinib Placebo (N=12) (N=12) EASI 75 (%pts) 75 20* IGA 0 or 1 (%pts) 33 0 EASI 50 (%pts) 92 30* EASI 90 (%pts) 25 0 Change EASI Mean % Reduction 72 40* Flare (requiring rescue meds) (%pts) 0 17 *2 placebo pa
Slide 12: Mean Percent Reduction in EASI Cohort 4
Mean Percent Reduction in EASI Cohort 4 Increased efficacy with longer duration of treatment (8 weeks)
Slide 13: Percentage Patients Achieving EASI75 and IGA 0/1
Percentage Patients Achieving EASI75 and IGA 0/1 Responses maintained in drug-free follow up 100% EASI75 – End of Treatment 90% EASI75 – Follow-up IGA 0/1 – End of Treatment 80% IGA 0/1 – Follow-up 70% % Patients 60% 50% 40% 30% 20% 10% 0% W4/End of Treatment 30-Day 60-Day 90-Day W8/End of Treatment
Slide 14: Efficacy in Patients with Prior Systemic Therapy (Cohorts 1–4)
Efficacy in Patients with Prior Systemic Therapy (Cohorts 1–4) Comparable efficacy in patients with prior systemic therapy All Patients (Cohorts 1–4) Prior Systemic Therapy (Cohorts 1–4)
Slide 15: Response in Systemic Treatment Resistant Patients
Response in Systemic Treatment Resistant Patients Cohorts 3 & 4 Study Baseline Age/Gender Prior Treatment Resistant % EASI change Treatment EASI Soquelitinib 60/F Dupilumab 24.6 –91% Soquelitinib 18/M Dupilumab, anti-OX40L 23.8 –96% Dupilumab, methotrexate, Soquelitinib 52/M 41.5 –27% upadacitinib D
Slide 16: Safety Summary
Safety Summary 4-week 8-week Cohorts 1–3 Cohort 4 Soquelitinib Placebo Soquelitinib Placebo (n=36) (n=12) (n=12) (n=12) Subjects with AEs* 15 (41.7%) 4 (33.3%) 5 (41.7%) 6 (50%) Severe (Grade ≥3) AEs 0 0 0 0 Serious AEs 0 0 0 0 AEs leading to study drug 0 0 0 0 discontinuation *All Grade 1-2 AEs not
Slide 17: Safety Summary
Safety Summary All reported AEs Cohorts 1–3 Cohort 4 SQL (n=36), n (%) PBO (n=12), n (%) SQL (n=12), n (%) PBO (n=12), n (%) Subjects with any TEAE 15 (41.7) 4 (33.3) 5 (41.7) 6 (50) Headache 4 (11.1) 1 (8.3) 4 (33.3) 0 (0) Abdominal pain upper 1 (2.8) 0 (0) 0 (0) 1 (8.3) Nausea 1 (2.8) 1 (8.3) 0 (0
Slide 18: Conclusions
Conclusions Immunologic effects of soquelitinib • Soquelitinib is a first-in-class selective oral ITK inhibitor that suppresses Th2 and Th17 inflammatory responses and increases Tregs TH1 T-bet • Clean safety profile with no infection signal and no lab APC abnormalities IL-4 IL-5 • Early and deep re
Slide 19: We thank the clinical trial participants and collaborating sites
We thank the clinical trial participants and collaborating sites: Apex Clinical Research, Arkansas Research Trials, Best Skin Research, Cahaba Dermatology and Skin Health Research Center, Center For Dermatology Clinical Research, Empire Clinical Research, Equity Medical - New York and Kentucky, Nobl
Corvus Pharmaceuticals — Society for Investigative Dermatology 2026 on 6ix